Tremelimumab plus durvalumab combined to metronomic oral vinorelbine: Results from the breast cancer cohort of the phase II MOVIE study [0.03%]
特莫珠单抗联合度伐利尤单抗与口服小剂量长春瑞滨联合治疗：II期MOVIE研究乳腺癌队列的疗效分析
T De La Motte Rouge,J-S Frenel,C Cropet et al.
T De La Motte Rouge et al.
Purpose: MOVIE assessed the enhancement of immunotherapy activity in advanced breast cancer (BC) tumors with metronomic chemotherapy associated to dual ICI combination. ...
Long-term survival outcomes of male breast cancer: the propensity score matching analysis of nationwide registry database [0.03%]
基于全国登记数据库的男性乳腺癌长期生存结局：倾向性评分匹配分析
Nayeon Choi,Sohyun Moon,Jin Sung Kim et al.
Nayeon Choi et al.
Background: s: Few studies have examined the prognosis of male breast cancer patients in Western countries. However, data on the long-term outcomes in Asian male patients are limited. Thus, we aimed to compare long-term s...
Addressing health literacy gaps in adjuvant endocrine therapy adherence: Post hoc insights from a randomized remote monitoring trial [0.03%]
辅助内分泌治疗依从性中的健康素养差距及后hoc随机远程监测试验见解
Ilana Graetz,Samuel Hernandez,Xin Hu et al.
Ilana Graetz et al.
Adjuvant endocrine therapy (AET) improves survival in hormone receptor-positive breast cancer, yet adherence is often lower among individuals with limited health literacy. This post hoc analysis of the THRIVE trial examined whether health l...
The association between breast fibrosis, cosmetic outcomes, and long-term health-related quality of life after breast-conserving therapy: a multicenter cross-sectional observational cohort study [0.03%]
乳腺保守治疗后乳腺纤维化与美容效果及长期健康相关生活质量之间的关联：一项多中心横断面观察性队列研究
M C A W Notenboom,T M A L Klem,C M E Contant et al.
M C A W Notenboom et al.
Background: Breast fibrosis is a well-known late side-effect of breast-conserving therapy (BCT) and may lead to breast retraction, asymmetry, and pain. Since life expectancy of breast cancer patients has significantly imp...
Pascal Pujol,Laurent Remontet,Bénédicte Lapôtre-Ledoux et al.
Pascal Pujol et al.
The incidence of early-onset breast cancer (EOBC) has recently been shown to be increasing over time in the US and the UK. Using national cancer registries data including 229,352 BC cases, we show that the incidence rate of EOBC in France i...
A preoperative predictive model for margin status in breast-conserving surgery [0.03%]
乳腺保守手术中切缘状态的术前预测模型
Xinyu Liu,Yan Liu,Shichao Zhang et al.
Xinyu Liu et al.
Background and purpose: Positive margins after breast-conserving surgery (BCS) not only frequently necessitate re-excision but also represent the most significant risk factor for local recurrence. This study aimed to iden...
Cancer outcomes in patients eligible for adjuvant cyclin-dependent kinase 4 and 6 inhibitors but spared adjuvant chemotherapy by Oncotype Dx: A multicenter retrospective GBECAM 0520 study [0.03%]
ONCOtype DX低风险的乳腺癌患者中避免辅助化疗而使用细胞周期蛋白依赖性激酶4/6抑制剂后的预后结果：一项GBECAM 0520多中心回顾性研究
Leandro Jonata de Carvalho Oliveira,Daniela Dornelles Rosa,Artur Katz et al.
Leandro Jonata de Carvalho Oliveira et al.
Background: In pivotal CDK4/6 inhibitor (CDK4/6i) adjuvant trials, most patients received chemotherapy (CT). However, the role of CDK4/6i in patients spared CT by a genomic signature remains unclear. We investigated the p...
Cost-effectiveness of sacituzumab tirumotecan versus chemotherapy for patients with metastatic triple-negative breast cancer in China [0.03%]
司妥昔单抗妥莫珠单抗 vs 化疗治疗中国转移性三阴乳腺癌患者的成本效果分析
Yamin Shu,Ying Tang,Yiling Ding et al.
Yamin Shu et al.
Purpose: Sacituzumab tirumotecan (sac-TMT), a trop-2-targeted antibody-drug conjugate, has demonstrated significant clinical benefit in the OptiTROP-Breast01 trial for patients with advanced or metastatic triple-negative ...
Artificial intelligence in breast cancer radiotherapy: Insights from the Toolbox Consortium Delphi study [0.03%]
基于工具箱小组德尔菲研究的人工智能在乳腺癌放射治疗中的应用
Orit Kaidar-Person,André Pfob,Vincenzo Valentini et al.
Orit Kaidar-Person et al.
Artificial intelligence (AI) is being incorporated in several breast cancer care domains, including for radiation therapy (RT). Herein we provide a review about AI for the management and planning of RT for breast cancer, which is part of th...
Central nervous system relapse in triple-negative breast cancer patients achieving pathological complete response after neoadjuvant chemotherapy: A retrospective cohort analysis [0.03%]
新辅助化疗后达到病理完全缓解的三阴性乳腺癌患者的中枢神经系统复发：一项回顾性队列分析
Gabriel Berlingieri Polho,Yumi Ricucci Shinkado,Leticia Kimie Murazawa et al.
Gabriel Berlingieri Polho et al.
Triple-negative breast cancer (TNBC) is associated with an increased risk of distant metastases. While pathological complete response (pCR) after neoadjuvant chemotherapy predicts favorable outcomes, data suggest it may not uniformly protec...